Science

Heidi Ko: Our latest mini-review on HER2 as a tumor-agnostic biomarker

Heidi Ko/LinkedIn

Mar 4, 2025, 11:22

Heidi Ko: Our latest mini-review on HER2 as a tumor-agnostic biomarker

Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, shared an article on LinkedIn:

“Excited to share that our latest mini-review on HER2 as a tumor-agnostic biomarker is now published in Frontiers in Oncology!

We delved into the evolving role of HER2 overexpression in various solid tumors and discussed how advancements in Antibody Drug Conjugates, particularly T-DXd, are transforming treatment strategies in solid malignancies.

We also addressed the challenges in HER2 testing across pan solid tumors and the potential of NGS and AI algorithms to enhance diagnostic accuracy.

Check out the full article here.”

From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates.

Authors: Heidi C Ko, et al.

More posts featuring Heidi Ko.

antibody biomarker cancer fight against cancer Frontiers in Oncology Global fight against cancer Heidi Ko HER2 Labcorp Drug Development OncoDaily Oncology T-Dxd

Beyond the Red Carpet: Oscar Winners and Nominees Who Fought Cancer

Oncologist Near Me – Lidia Schapira: A Leader in Cancer Care and Medical Education

CancerWorld welcomes their Co-Editors-in-Chief

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma